Novartis Can't Block Generics Ahead Of MS Patent Grant

By Lucia Osborne-Crowley (May 9, 2022, 7:30 PM BST) -- A judge has refused to hand pharma giant Novartis an injunction stopping several generic-drug makers from entering the market for a multiple sclerosis drug that it is soon to be granted a patent for, saying monetary damages are more appropriate.

High Court Judge Peter Roth said in a newly public April 26 ruling that Novartis is not entitled to an order barring Teva UK Ltd., Dr Reddy's Laboratories (UK) Ltd. and several other generic-drug makers from selling their own versions of the prescription drug fingolimod. The drug, which Novartis markets under the brand name Gilenya, is used to treat relapsing-remitting multiple sclerosis....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!